Interview with Odnir Finotti, Executive President, Pró Genéricos
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
Address: Rua Alvorada, 1280
CEP : 04550-004
Rua Alvorada, 1280 CEP : 04550-004 São Paulo – SP,Brazil
Tel: (11) 3897-9767
Web: http://www.progenericos.org.br/
Founded in January 2001, the Brazilian Association of Generic Drugs – Pró Genéricos brings together leading laboratories working in the production and marketing generic drugs in the country.
Pró Genéricos is a nonprofit entity whose main mission is to contribute to the improvement of access to medicines in Brazil through the consolidation and expansion of the generics market.
Together, the members of the Pro Generic constitutes around 90% of sales in the generics business in the country. Pro Generic connects various sectors of society, institutions of public and private channels with the actions of its members, giving substance to public debate on issues relevant to the health sector and the development of the pharmaceutical industry in the country .
Since September 2005, Pró Genéricos has been part of the Generic IGPA (International Generic Pharmaceutical Alliance), as an observer. Founded in March 1997, the IGPA is an international organization that seeks to ensure consumer access to medicines that meet quality and economy.
Industry Association.
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
In a wide-ranging interview, AbbVie’s Flavio Devoto outlines some of the key access challenges and opportunities in the diverse Latin American pharma market, his approach to being a transformational leader…
The latest from Brazilian Pharma, including the controversial proposal to transform Brazil’s regulatory agency, ANVISA; Ease Labs’s canabidiol approval, Biolab’s international expansion ambitions and Eurofarma’s multiple myeloma deal. ANVISA’s…
Sarah Aiosa oversees the entire Latin America region for MSD, where the global giant is looking to build on its 100-year legacy by better addressing the continent’s health inequities and…
Latin America is a rapidly growing market for the global medtech industry, offering significant opportunities. With a population of over 650 million people, the region boasts a large and growing…
Guilherme Marques, president of Siemens Healthineers LatAm, discusses the health tech giant’s regional strategy, covering how the firm rides out the region’s economic and political storms, its participation in disease…
Latin America is a crucial region for medtech market leader Medtronic. Home to 20,000 of the company’s 95,000+ global workforce, 12 manufacturing plants, and ten commercial organisations, Medtronic LatAm grew…
In 2019 the pharma industry financed some 700 clinical studies in Latin America with investments of more than USD one billion and according to FIFARMA, the leading association of innovators…
Renata Mihich, a 25-year DHL veteran, recently took on a new role as Head of LatAm for Italian healthcare logistics specialist BOMI GROUP. At a moment of career transformation, BOMI…
While regulatory agencies in several Latin American countries have made significant efforts to improve processes and accelerate approval times, a number of access hurdles still remain across the region. Here,…
Rolf Hoenger describes how Roche is driving access and awareness for innovative medicines in Latin America and weighs in on a number of important topics, from regulatory harmonisation in the…
After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV…
Although Brazil is one of the world’s top pharma markets, with the highest market value in Latin America, and has made major strides towards universal healthcare, the country continues to…
See our Cookie Privacy Policy Here